Late-stage round brings in $25mm for Synageva BioPharma

Synageva BioPharma Corp. (developing monoclonal antibody therapeutics for rare conditions) brought in $25mm in what appears to be its Series G financing. All of the company’s lead investors contributed to the round, which will support Phase I trials for its lead enzyme replacement therapy SBC102 for lysosomal acid lipase deficiency and preclinical studies for four other rare disease compounds. The company raised a total of $45mm in its three-tranche Series F round in which New Leaf Venture Partners, Hunt BioVentures, Yasuda Enterprise Development, Baker Brothers Investments, Tullis Dickerson, and Four Partners participated.